Protective brain cells may be quietly driving age-related cognitive decline
Oligodendrocytes, the cells that make myelin, may turn harmful with age and speed cognitive decline, pointing to a drug target already used in other brain disorders.
Summary
Brain aging may involve an unexpected culprit: oligodendrocytes, the cells that build and maintain myelin, the insulating coat around nerve fibers. Researchers from the University of Edinburgh and the UK Dementia Research Institute used data from the Lothian Birth Cohort 1936, which tracked thinking skills from childhood into old age. Donated brain tissue from people who had declined faster showed fewer large nerve fibers and an abnormal buildup of unhealthy myelin, especially around the large fibers that remained. These changes tracked how quickly abilities declined, not how people scored at one point in time. Experiments in mice supported the idea that dysfunctional myelin-producing cells can damage nerve fibers and impair cognition. The pathway involved is already targeted by drugs used for other neurological conditions, so existing medicines might one day be repurposed to protect the aging brain. The work, published in Nature Medicine, challenges the assumption that these cells are always helpful and suggests that more myelin is not always better.
Detailed Summary
Cognitive decline is one of the most feared parts of aging, yet people differ widely in how quickly their thinking skills fade. A new Nature Medicine study from the University of Edinburgh and the UK Dementia Research Institute suggests one reason: cells long considered purely protective may become part of the problem.
The team drew on the Lothian Birth Cohort 1936, a group whose cognitive abilities have been tracked since childhood. Between ages 70 and 82, participants were tested on memory, processing speed and spatial reasoning. Of 1,091 enrolled, 866 completed additional testing after age 70. Nearly everyone declined, but the rate varied considerably, giving researchers a natural comparison between faster and slower decliners.
In brain tissue donated after death, people with greater decline had fewer large nerve fibers and an abnormal accumulation of unhealthy myelin, the insulating coating that speeds electrical signals. The changes were most pronounced around the large fibers that remained. Importantly, these features were linked to the rate of decline over time rather than to performance at any single age. That distinction matters because it ties the biology to the trajectory of aging, not just to a snapshot of ability.
The researchers then focused on oligodendrocytes, the cells that produce and maintain myelin. Experiments in mice, together with the human tissue findings, indicated that when these cells become dysfunctional with age they can overproduce abnormal myelin, damage nerve fibers and interfere with cognition. The authors also note that drugs acting on the pathway involved are already used for other neurological conditions, raising the possibility of repurposing them.
For readers, this is not yet an actionable intervention. The human data come from a single cohort and are observational, and mouse results do not always translate. No treatment for age-related decline has been tested here. Still, the work reframes myelin maintenance as a possible target for preserving brain function, and it highlights oligodendrocyte health as a new area to watch in brain aging research.
Key Findings
- Faster cognitive decline in older adults was linked to fewer large nerve fibers and abnormal, unhealthy myelin buildup in brain tissue.
- Myelin abnormalities tracked the rate of decline over ages 70 to 82, not performance at a single age.
- Oligodendrocytes, long viewed as purely beneficial, may become dysfunctional with age and damage nerve fibers.
- Mouse experiments supported a causal role for dysfunctional myelin-producing cells in impaired cognition.
- Drugs targeting the implicated pathway already treat other neurological conditions, suggesting possible repurposing for brain aging.
Methodology
This is a news report summarizing a peer-reviewed Nature Medicine study from the University of Edinburgh and UK Dementia Research Institute. The evidence combines a long-running human cohort with postmortem brain tissue analysis and mouse experiments. The source is a university press release relayed by ScienceDaily, so details are condensed.
Study Limitations
The article excerpt is truncated, so the specific pathway, drugs and mouse methods are not named. Postmortem tissue came from a subset of participants and shows association, while mouse findings may not carry over to humans. Check the original Nature Medicine paper for sample sizes, effect sizes and the drug candidates.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: